HF Advisory Group LLC Has $1.47 Million Stock Holdings in Sanofi (NASDAQ:SNY)

HF Advisory Group LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 13.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,572 shares of the company’s stock after selling 4,240 shares during the period. HF Advisory Group LLC’s holdings in Sanofi were worth $1,474,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of SNY. Brighton Jones LLC boosted its stake in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after buying an additional 1,869 shares during the last quarter. abrdn plc raised its holdings in shares of Sanofi by 25.6% in the 4th quarter. abrdn plc now owns 314,180 shares of the company’s stock valued at $15,153,000 after purchasing an additional 64,095 shares during the period. Yousif Capital Management LLC raised its holdings in shares of Sanofi by 53.2% in the 4th quarter. Yousif Capital Management LLC now owns 59,611 shares of the company’s stock valued at $2,875,000 after purchasing an additional 20,690 shares during the period. Leo Wealth LLC raised its holdings in shares of Sanofi by 5.9% in the 4th quarter. Leo Wealth LLC now owns 26,669 shares of the company’s stock valued at $1,286,000 after purchasing an additional 1,487 shares during the period. Finally, Strategic Financial Concepts LLC bought a new stake in shares of Sanofi in the 4th quarter valued at about $667,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price on the stock. Finally, Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $63.33.

Sanofi Stock Up 0.6%

Sanofi stock opened at $49.50 on Thursday. The stock has a market cap of $121.40 billion, a P/E ratio of 19.88, a P/E/G ratio of 1.01 and a beta of 0.50. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company’s 50-day moving average price is $51.91 and its two-hundred day moving average price is $51.92.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion for the quarter, compared to analysts’ expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The business’s revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.78 EPS. As a group, analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. The ex-dividend date is Friday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi’s dividend payout ratio (DPR) is currently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.